Losses on Asset Disposals and Impairment Losses
First written in FY2022-Q1. 4 of 5 entries say "Materialised", first in FY2022. Latest entry: FY2024.
Nippon Express Holdings moved to the "Worse" side of this theme in 2023, 3 years after the typical company in this theme (2020).
The whole theme swung hardest in 2025: 43 of 77 companies on the "Worse" side.
60 other companies' latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「The breakdown by type of asset of the assets recognized as impairment losses during the current consolidated fiscal year is as follows. The losses are included in “Other expenses” in the consolidated income statement.」
Impairment losses of ¥9.747 billion were recorded in fiscal 2024: ¥6.282 billion for the consolidated freight business, ¥2.938 billion for the pharmaceutical business and ¥327 million for idle assets and other assets in the Americas. - FY2024-Q1MaterialisedAnnual report
「In connection with executing the agreement for this business integration, we recognized an impairment loss of ¥6,592 million during the first nine months of the current fiscal year and recorded it under “Other expenses” in the condensed interim consolidated income statement.」
An impairment loss of ¥6.592 billion was recorded in connection with the integration agreement for the consolidated freight business and other operations, providing a new concrete instance of the risk. - FY2023MaterialisedAnnual report
「In the annual impairment test of the cash-generating unit containing NPL’s goodwill, fair value less costs of disposal was used as the recoverable amount. Because it was below the carrying amount of the assets including goodwill, we recorded an impairment loss including goodwill of ¥5,102 million.」
In fiscal 2023, impairment losses of ¥3.163 billion in the pharmaceutical business and ¥5.102 billion in NX NP Logistics were recorded, demonstrating the materialization of the asset-disposal and impairment risk. - FY2022MaterialisedAnnual report
「Based on the revised business plans, we conducted impairment tests, reduced the carrying amount of the business assets to their recoverable amount, and recorded an impairment loss of ¥19,978 million.」
A review of the pharmaceutical business plan resulted in an impairment loss of ¥19.978 billion, demonstrating the materialization of the asset-disposal and impairment risk. - FY2022-Q1First statedAnnual report
「Depending on future economic conditions and customer trends, assets may be disposed of or returned earlier than originally planned, resulting in temporary losses or impairment losses and potentially adversely affecting operating results and financial position.」
The possibility of early disposal or impairment of domestic and overseas logistics facilities due to economic and customer trends is described.